Provided by Tiger Trade Technology Pte. Ltd.

Mirum Pharmaceuticals, Inc.

96.72
+0.41000.43%
Post-market: 96.720.00000.00%16:18 EDT
Volume:367.57K
Turnover:35.62M
Market Cap:6.28B
PE:-6.87
High:97.85
Open:96.31
Low:95.49
Close:96.31
52wk High:130.00
52wk Low:63.23
Shares:64.93M
Float Shares:56.42M
Volume Ratio:0.72
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.0800
EPS(LYR):-0.4700
ROE:-702.97%
ROA:-6.79%
PB:-602.59
PE(LYR):-205.79

Loading ...

Earnings Flash (MIRM) Mirum Pharmaceuticals Posts Q1 Loss $13.43 a Share, vs. FactSet Est of $0.37 Loss

MT Newswires Live
·
May 07

Mirum Q1 FY26 operating loss widens to $789.47 million; revenue rises 43.3% to $159.88 million

Reuters
·
May 07

Mirum Pharmaceuticals Q1 EPS $(13.43) Misses $(0.37) Estimate, Sales $159.882M Beat $149.535M Estimate

Benzinga Earnings
·
May 07

BRIEF-Mirum Pharmaceuticals Q1 Product Sales USD 159.882 Million

Reuters
·
May 07

Mirum Pharmaceuticals Inc - Raises 2026 Net Product Sales Guidance to $660-$680 Mln

THOMSON REUTERS
·
May 07

Mirum Pharmaceuticals Q1 Operating Income USD -789.465 Million

THOMSON REUTERS
·
May 07

Mirum Pharmaceuticals Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 06

Mirum Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 05

BUZZ-U.S. STOCKS ON THE MOVE-Mirum Pharma, eBay, FedEx

Reuters
·
May 05

Shares of Mirum Pharmaceuticals Hit All-Time High on Phase 2B Results for Liver Treatment

Dow Jones
·
May 04

Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright

TIPRANKS
·
May 04

Mirum Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $175 From $150

THOMSON REUTERS
·
May 04

Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
May 04

Mirum's rare liver disease drug meets main goal in mid-stage study

Reuters
·
May 04

Mirum Pharmaceuticals Inc : Leerink Partners Raises Target Price to $131 From $118

THOMSON REUTERS
·
May 04

Mirum announces primary endpoint met in VISTAS Phase 2b study of volixibat

TIPRANKS
·
May 04

BRIEF-Mirum Pharmaceuticals Announces Primary Endpoint Met In Vistas Study Of Volixibat In Patients With Primary Sclerosing Cholangitis

Reuters
·
May 04

Mirum says volixibat meets primary endpoint in VISTAS Phase 2b PSC trial

Reuters
·
May 04

Mirum Pharmaceuticals Announces Primary Endpoint Met in Vistas Study of Volixibat in Patients With Primary Sclerosing Cholangitis

THOMSON REUTERS
·
May 04

Mirum Pharmaceuticals Inc - Pre-Nda Meeting for Volixibat in Psc Scheduled With FDA Summer 2026; Nda Submission Planned H2 2026

THOMSON REUTERS
·
May 04